Marilyn K Csete Glassberg

Dr Glassberg is a pulmonologist specializing in interstitial and rare lung diseases. She has conducted NIH-funded, industry-sponsored, and investigator-initiated clinical trials in patients with idiopathic pulmonary fibrosis (IPF), pulmonary hypertension, and lymphangioleiomyomatosis. She has completed the first clinical trial on the safety of intravenous infusion of bone-marrow derived mesenchymal stem cells (MSCs) in patients with IPF endorsed by the US Food and Drug Administration (FDA) and reported safety.

Latest posts by Marilyn K Csete Glassberg (see all)